Hope for Hepatitis Drug

  • Author: Vikki Cantrill
  • Published: 23 May 2013
  • Copyright: Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
  • Source / Publisher: Journal of Organic Chemistry/ACS Publications
  • Associated Societies: American Chemical Society (ACS), USA
thumbnail image: Hope for Hepatitis Drug

Hepatitis B is one of the most common infections worldwide, affecting around two billion people. A number of drugs exist to treat this infection, which untreated can result in cirrhosis of the liver or liver cancer. The patent of one such drug, entecavir (pictured), which shows no significant adverse effects and has a low risk of inducing long-term resistance, expires in 2015 in the US making this drug attractive as a generic target.


A new route to entecavir, developed by Xavier Ariza, Jaume Farras̀, and colleagues, Universitat de Barcelona, and colleagues from Esteve Química, both Spain, starts from commercially available acyclic precursors. The key points of this 11-step synthesis are a stereoselective boron−aldol reaction, a Cp2TiCl-catalyzed intramolecular radical addition of an epoxide to an alkyne, and coupling with a purine derivative by a Mitsunobu reaction. The products in the final steps are purified by crystallization making this attractive sequence amenable to scale-up.


Article Views: 2553

Sign in Area

Please sign in below

Additional Sign In options

Please note that to comment on an article you must be registered and logged in.
Registration is for free, you may already be registered to receive, e.g., the newsletter. When you register on this website, please ensure you view our terms and conditions. All comments are subject to moderation.

Article Comments - To add a comment please sign in

Bookmark and Share

If you would like to reuse any content, in print or online, from ChemistryViews.org, please contact us first for permission. more


CONNECT:

ChemistryViews.org on Facebook

ChemistryViews.org on Twitter ChemistryViews.org on YouTube ChemistryViews.org on LinkedIn Sign up for our free newsletter


A product of ChemPubSoc Europe (16 European Chemical Societies)and Wiley-VCH